Form 8-K - Current report:
SEC Accession No. 0001641172-25-008455
Filing Date
2025-05-05
Accepted
2025-05-05 06:05:20
Documents
15
Period of Report
2025-05-02
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 47092
2 EX-3.1 ex3-1.htm EX-3.1 15805
  Complete submission text file 0001641172-25-008455.txt   285495

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ptix-20250502.xsd EX-101.SCH 3515
4 XBRL DEFINITION FILE ptix-20250502_def.xml EX-101.DEF 26546
5 XBRL LABEL FILE ptix-20250502_lab.xml EX-101.LAB 36500
6 XBRL PRESENTATION FILE ptix-20250502_pre.xml EX-101.PRE 25170
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5617
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 25910770
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)